Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Correct Health Care ; 19(3): 194-210, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23711801

RESUMO

This study profiled 2,913 adults aged 50 and older sentenced to a statewide correctional system and their parole eligibility status with implications for community reintegration, resettlement, and recovery needs. The research team developed the Correctional Tracking Data Extraction Tool to gather official data and personal and legal characteristics from a state department of corrections website. The majority of older prisoners were men from racial/ethnic minorities between the ages of 50 and 59 with a range of minor to serious offenses. Time served in prison ranged from 1 month to 45 years; more than 40% were eligible for parole within 5 years. These findings underscore the need for an intervention that can address the differing typologies and individual-level and systemic issues that gave rise to the aging prisoner population. Promising practices that address elements of a conceptual model in prison and community reintegration and recovery for older adult prisoners are reviewed.


Assuntos
Envelhecimento , Prisioneiros/psicologia , Ajustamento Social , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estados Unidos
2.
Semin Ophthalmol ; 21(4): 215-22, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17182409

RESUMO

OBJECTIVE: To report the abnormal multifocal electroretinogram (mfERG) findings in two cases of presumed ethambutol toxicity. DESIGN: Retrospective observational case series. PARTICIPANTS: Two patients with ethambutol toxicity and visual loss. TESTING: Multifocal electroretinography. MAIN OUTCOME MEASURE: Waveform measurements on multifocal electroretinography. RESULTS: Two patients with bilateral visual loss due to ethambutol toxicity underwent mfERG testing that disclosed both diffuse and central field loss compatible with retinal dysfunction as a contributing mechanism to the visual field loss. CONCLUSION: Ethambutol toxicity affects not only the optic nerve but probably other retinal elements based upon abnormal mfERG findings.


Assuntos
Antituberculosos/efeitos adversos , Eletrorretinografia , Etambutol/efeitos adversos , Retina/efeitos dos fármacos , Doenças Retinianas/induzido quimicamente , Transtornos da Visão/induzido quimicamente , Idoso de 80 Anos ou mais , Feminino , Humanos , Pessoa de Meia-Idade , Retina/fisiopatologia , Doenças Retinianas/diagnóstico , Doenças Retinianas/fisiopatologia , Transtornos da Visão/diagnóstico , Transtornos da Visão/fisiopatologia , Acuidade Visual , Testes de Campo Visual , Campos Visuais
3.
J Interferon Cytokine Res ; 22(5): 549-54, 2002 May.
Artigo em Inglês | MEDLINE | ID: mdl-12060493

RESUMO

Hepatitis C virus (HCV) infection is resistant to interferon-alpha (IFN-alpha) in some patients. The mechanism of this resistance is unknown. Interleukin-1 receptor antagonist (IL-1Ra) is induced by IFN-alpha and is a good indicator of IFN activity. In the current study, we compared IL-1Ra levels in rapid virologic responders and flat responders who showed resistance to IFN. Three groups of patients were examined, including those who received a single dose of consensus IFN (IFN-con1), patients who received daily IFN-con1 for 1 week, and patients who received IFN-con1 daily for 24 weeks. Serum IL-1Ra, IL-6, and HCV RNA were measured serially in all groups. Serum IL-1Ra levels increased rapidly in all patients with hepatitis C after IFN-alpha administration, irrespective of their virologic response. IL-1Ra levels remained elevated at 1 week but were similar to baseline by week 2 of treatment in patients receiving continuous therapy. IL-6 levels also increased acutely but rose more slowly than IL-1Ra levels. The increase in IL-1Ra and IL-6 observed in both flat and rapid virologic responders indicates that IFN receptors are functioning in patients with IFN-resistant hepatitis C and that the lack of response is related to other virologic or immunologic factors.


Assuntos
Antivirais/uso terapêutico , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/imunologia , Interferon Tipo I/uso terapêutico , Sialoglicoproteínas/biossíntese , Adulto , Idoso , Farmacorresistência Viral , Hepacivirus/efeitos dos fármacos , Hepacivirus/isolamento & purificação , Hepatite C Crônica/virologia , Humanos , Interferon-alfa , Proteína Antagonista do Receptor de Interleucina 1 , Pessoa de Meia-Idade , RNA Viral/sangue , Proteínas Recombinantes , Sialoglicoproteínas/sangue , Viremia/tratamento farmacológico , Viremia/imunologia , Viremia/virologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...